Understanding the Rise in Cannabis Treatment Demand

A "joint" study in the Netherlands, Germany and the United Kingdom



European Monitoring Centre for Drugs and Drug Addiction

TDI Expertmeeting 20-22 september 2012



The University of Manchester





Martin Steppan IFT München

 \mathbf{IFT}

In cooperation with:

Andrew Jones (UK) Jeroen Wisselink (NL) Wil Kuijpers (NL)



The University of Manchester



Background

• For some years Treatment Systems have reported an increase in Cannabis Treatment Demand

(Wisselink & Kuipers, 2012; Steppan, Pfeiffer-Gerschel & Künzel, 2009-2011; Roxburgh, Donmall, Wright& Jones, 2011

- EMCDDA, 2004 [selected issue])
- There is yet no evidence to understand this situation
- Research is needed that combines several scientific approaches (incidence, prevalence estimation, EMCDDA cross-country comparisons etc.) to give explanations for this situation





Formula for Treatment Demand



Possible Explanations (hypotheses) for a Rise in Treatment Demand

- Changes in treatment probability (A)
 - Increased treament probability
 - Higher societal awareness of cannabis as a serious problem
 - Higher treatment supply due to societal awareness
 - Better supply with focused cannabis treatment
 - Higher acceptance of therapy in general
 - Obligation for therapy due to legal authorities
 - Greater emphasis on young people services
 - Accelerated treatment probability
- Changes in incidence in the past (B)
 - Increased incidence of (pathological) cannabis consumption
 - Higher prevalence among general population
 - Equal prevalence, but higher rate of serious consumption (e.g. via higher doses of THC; higher popularity of serious application forms, e.g. "bong")
 - Higher supply with cannabis products, e.g. "coffee shops" in the Netherlands
- Explanations (A+B)
 - change in legal classification making use more 'open'





Research Questions

- <u>Is there really</u> an increase in Cannabis treatment demand in NL, GER, UK?
- What is it like (linear, logistic, etc.)?
- Can it be traced back to an increased incidence in the last decade? (bad news [hypotheses A])
- Can it be traced back to an increased probability to seek treatment? (good news [hypotheses B])
- Can it be traced back to both causes? (good and bad news)
- Which hypotheses can be eliminated?





Method and Data

Method:

- Hypothesis elimination approach
 - (A) Cross-country comparisons (UK, GER, NL)
 - (B) Subregional comparisons (NL municipalities)
 - (C) Relative Incidence Estimation (GER, NL)

Data:

- National Treatment Documentation Systems
 Ladis (NL), DSHS (Germany), NDTMS (UK)
 - Literature research (previous studies)





Results (A): EMCDDA-Reitox-Reports



NB: Treatment in overall numbers (% of all clients). Average of trends (%) within countries. Countries providing data: CZ, DK, DE, EL, ES, NL, SL, SK, FI, SE. In Sweden, data for 1996–99 are from hospital treatment: the number of cannabis cases is thus relatively low compared with other years. Sources: Reitox national reports 2003.







Results (A):

Rise in Cannabis Treatment Demand









Results (A): Changes in Cannabis prevalence among general population



Results (B): Rise in Cannabis TD in the ten biggest cities in the Netherlands







Results (B): Linear Trend?







Summary (A): Cross-country comparisons

- Consistent increase in cannabis treatment demand in several countries since 1996 (EMCDDA, GER, UK, NL)
- No relationship with cannabis prevalence in the general population (GER, UK, NL)





Results (B): Latent Growth Curve Modelling



Results (B): Latent Growth Curve Modelling



Summary (B): Subregional analysis (NL)

- Consistent linear increase in cannabis treatment demand across Dutch subregions
- Increase in cross-regional cannabis treatment demand in NL is mainly associated with
 - ,destructurization' of traditional familial bonds (in municipalities with more singles and more divorces)
 - other demographic and behavioural predictors (lower educational level, lower percentage of migrants, lower but more often regular income, lower age at first use)





Results (3): Relative Birth Cohort Incidence Estimation (NL)









(3) Relative Birth Cohort Incidence and Treatment Demand Forecast



Average Age at onset of treatment (26 years)







Summary (C): Relative Incidence Estimation NL

- Birth cohort incidence peak in 1962 and 1984
- Combined with the typical age at onset of treatment the increase in cannabis treatment demand can be explained (nearly perfectly)







Summary

- <u>(A): Cross-country comparisons (EMCDDA, UK, GER, NL):</u>
 - Consistent increase in cannabis treatment demand not related to changes in prevalence among the general population
- (B): Subregional analysis (NL):
 - Consistent linear increase in cannabis treatment demand best explained by social structure determinants
- (C): Relative Incidence Estimation
 - High concordance of incidence estimates with lagged treatment demand figures
 - suggesting a decline within few years





Which hypotheses can be eliminated?

- Changes in treatment probability (A)
 - Increased treament probability
 - Higher societal awareness of cannabis as a serious problem
 - Higher treatment supply due to societal awareness
 - Focused cannabis treatment due to societal awareness
 - Higher acceptance of therapy in general
 - Obligation for therapy due to legal authorities
 - Accelerated treatment probability
- Changes in incidence in the past (B)
 - Increased incidence of (pathological) cannabis consumption
 - Higher prevalence among general population
 - Equal prevalence, but higher rate of serious consumption (e.g. higher doses of THC; higher popularity of serious application forms, e.g. "bong")
 - Higher supply with cannabis products, e.g. "coffee shops" in the Netherlands





Answers to Research Question

RESEARCH QUESTION:

- <u>Is there really</u> an increase in Cannabis treatment demand in NL, GER, UK? YES
- What is it like (linear, logistic, etc.)? QUITE LINEAR
- Can it be traced back to an increased incidence in the past? (bad news) PROBABLY YES
- Can it be traced back to an increased probability to seek treatment? (good news) NO EVIDENCE YET
- Can it be traced back to both causes? (good and bad news) NO EVIDENCE YET
- Which hypotheses can be eliminated?





End of presentation

Thank you very much for your attention!

 \mathbf{IFT}

For more information: <u>steppan@ift.de</u> <u>jeroen.wisselink@sivz.nl</u> <u>andrew.jones@manchester.ac.uk</u>

MANCHESTER 1824

The University of Manchester

